REFILE-Hims & Hers to sell Lilly's Zepbound on its telehealth platform
April 1 (Reuters) - Telehealth firm Hims & Hers Health HIMS.N said on Tuesday it plans to sell Eli Lilly's LLY.N weight-loss drug Zepbound on its platform.
Shares of the company were up 8.5% in afternoon trading.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey






